Diabetic Peripheral Neuropathy

Textbook of Diabetes: Fourth Edition

Volumn , Issue , 2010, Pages 615-634

  Ziegler, Dan ^a,b  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

Author keywords

Central nervous system dysfunction; Classification and epidemiology; Focal and multifocal neuropathies; Non pharmacologic treatment of painful neuropathy; Pharmacologic treatment of painful neuropathy; Quantitative sensory testing; Role of intensive diabetes therapy in treatment and prevention of diabetic neuropathy; Selective serotonin reuptake inhibitors (SSRI); Serotonin noradrenaline reuptake inhibitors (SNRI); Treatment based on pathogenetic concepts

Indexed keywords

EID: 84860733739     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781444324808.ch38     Document Type: Chapter

References (101)

1. Consensus statement. Report and recommendations of the San Antonio conference on diabetic neuropathy. Diabetes Care 1988; 11: 592-597.
2. Thomas PK. Metabolic neuropathy. J R Coll Phys Lond 1973; 7: 154-160.
3. Sima AAF, Thomas PK, Ishii D, Vinik A. Diabetic neuropathies. Diabetologia 1997; 40: B74-B77.
4. Shaw JE, Zimmet PZ, Gries FA, Ziegler D. Epidemiology of diabetic neuropathy. In: Gries FA, Cameron NE, Low PA, Ziegler D, eds. Textbook of Diabetic Neuropathy. Stuttgart/New York: Thieme, 2003; 64-82.
5. Ziegler D, Rathmann W, Dickhaus T, Meisinger C, Mielck A; KORA Study Group. Prevalence of polyneuropathy in pre-diabetes and diabetes is associated with abdominal obesity and macroangiopathy: the MONICA/KORA Augsburg Surveys S2 and S3. Diabetes Care 2008; 31: 464-469.
6. Resnick HE, Vinik AI, Schwartz AV, Leveille SG, Brancati FL, Balfour J, et al. Independent effects of peripheral nerve dysfunction on lower-extremity physical function in old age. The Women's Health and Aging Study. Diabetes Care 2000; 23: 1642-1647.
7. Forsblom CM, Sane T, Groop PH, Totterman KJ, Kallio M, Saloranta C, et al. Risk factors for mortality in type II (non-insulin-dependent) diabetes: evidence of a role for neuropathy and a protective effect of HLA-DR4. Diabetologia 1998; 4: 1253-1262.
8. Coppini DV, Bowtell PA, Weng C, Young PJ, Sönksen PH. Showing neuropathy is related to increased mortality in diabetic patients: a survival analysis using an accelerated failure time model. J Clin Epidemiol, 2000; 53: 519-523.
9. Abbott CA, Vileikyte L, Williamson S, Carrington AL, Boulton AJM. Multicenter study of the incidence of and predictive risk factors for diabetic neuropathic foot ulceration. Diabetes Care 1998; 21: 1071-1075.
10. Galer BS, Gianas A, Jensen MP. Painful diabetic neuropathy: epidemiology, pain description, and quality of life. Diabetes Res Clin Pract 2000; 47: 123-128.
11. Daousi C, Benbow SJ, Woodward A, MacFarlane IA. The natural history of chronic painful peripheral neuropathy in a community diabetes population. Diabet Med 2006; 23: 1021-1024.
12. Davies M, Brophy S, Williams R, Taylor A. The prevalence, severity, and impact of painful diabetic peripheral neuropathy in type 2 diabetes. Diabetes Care 2006; 29: 1518-1522.
13. Wu EQ, Borton J, Said G, Le TK, Monz B, Rosilio M, et al. Estimated prevalence of peripheral neuropathy and associated pain in adults with diabetes in France. Curr Med Res Opin 2007; 23: 2035-2042.
14. Ziegler D, Rathmann W, Dickhaus T, Meisinger C, Mielck A; KORA Study Group. Neuropathic pain in diabetes, pre-diabetes and normal glucose tolerance. The MONICA/KORA Augsburg Surveys S2 and S3. Pain Med 2009; 10: 393-400.
15. Ziegler D, Rathmann W, Meisinger C, Dickhaus T, Mielck A; KORA Study Group. Prevalence and risk factors of neuropathic pain in survivors of myocardial infarction with pre-diabetes and diabetes. The KORA Myocardial Infarction Registry. Eur J Pain 2008; 31: 464-469.
16. Boulton AJM, Scarpello JHB, Armstrong WD, Ward JD. The natural history of painful diabetic neuropathy: a 4-year study. Postgrad Med J 1983; 59: 556-559.
17. Young RJ, Ewing DJ, Clarke BF. Chronic and remitting painful diabetic neuropathy. Diabetes Care 1988; 11: 34-40.
18. Benbow SJ, Chan AW, Bowsher D, MacFarlane IA, Williams G. A prospective study of painful symptoms, small-fibre function and peripheral vascular disease in chronic painful diabetic neuropathy. Diabet Med 1993; 11: 17-21.
19. Archer AG, Watkins PJ, Thomas PK, Sharma AK, Payan J. The natural history of acute painful neuropathy in diabetes mellitus. J Neurol Neurosurg Psychiat 1983; 46: 491-499. 20 Ellenberg M. Diabetic neuropathic cachexia. Diabetes 1974; 23: 418-423.
20. Ellenberg M. Diabetic neuropathic cachexia. Diabetes 1974; 23: 418-423.
21. Steele JM, Young RJ, Lloyd GG, Clarke BF. Clinically apparent eating disorders in young diabetic women: associations with painful neuropathy and other complications. Br Med J 1987; 294: 859-866.
22. Caravati CM. Insulin neuritis: a case report. Va Med Mon 1933; 59: 745-746.
23. Dabby R, Sadeh M, Lampl Y, Gilad R, Watemberg N. Acute painful neuropathy induced by rapid correction of serum glucose levels in diabetic patients. Biomed Pharmacother 2009; 63: 707-709.
24. Llewelyn JG, Thomas PK, Fonseca V, King RHM, Dandona P. Acute painful diabetic neuropathy precipitated by strict glycemic control. Acta Neuropathol 1986; 72: 157-163.
25. Tesfaye S, Malik R, Harris N, Jakubowski JJ, Mody C, Rennie IG, et al. Arterio-venous shunting and proliferating new vessels in acute painful neuropathy of rapid glycaemic control (insulin neuritis). Diabetologia 1996; 39: 329-335.
26. Asbury AK. Focal and multifocal neuropathies of diabetes. In: Dyck PJ, Thomas PK, Asbury AK, Winegrad AI, Porte D, eds. Diabetic Neuropathy. Philadelphia: Saunders, 1987; 45-55.
27. Said G, Goulon-Goeau C, Lacroix C, Moulonguet A. Nerve biopsy findings in different patterns of proximal diabetic neuropathy. Ann Neurol 1994; 35: 559-569.
28. Said G, Elgrably F, Lacroix C, Planté V, Talamon C, Adams D, et al. Painful proximal diabetic neuropathy: inflammatory nerve lesions and spontaneous favorable outcome. Ann Neurol 1997; 41: 762-770.
29. Reske-Nielsen E, Lundbaek K. Pathological changes in the central and peripheral nervous system of young long-term diabetics. II. The spinal cord and peripheral nerves. Diabetologia 1968; 4: 34-43.
30. Slager U. Diabetic myelopathy. Arch Pathol Lab Med 1978; 102: 467-469.
31. Olsson Y, Säve-Söderbergh J, Sourander P, Angervall L. A pathoanatomical study of the central and peripheral nervous system in diabetics of early onset and long duration. Path Europ 1968; 3: 62-79.
32. Reske-Nielsen E, Lundbaek K, Rafaelsen OJ. Pathological changes in the central and peripheral nervous system of young long-term diabetics. I. Diabetic encephalopathy. Diabetologia 1965; 1: 233-241.
33. Ziegler D, Mühlen H, Dannehl K, Gries FA. Tibial nerve somatosensory evoked potentials at various stages of peripheral neuropathy in type 1 diabetic patients. J Neurol Neurosurg Psychiatry 1993; 56: 58-64.
34. Dejgaard A, Gade A, Larsson H, Balle V, Parving A, Parving HH. Evidence for diabetic encephalopathy. Diabet Med 1991; 8: 162-167.
35. Eaton SE, Harris ND, Rajbhandari SM, Greenwood P, Wilkinson ID, Ward JD, et al. Spinal-chord involvement in diabetic peripheral neuropathy. Lancet 2001; 358: 35-36.
36. Ziegler D, Langen K-J, Herzog H, Kuwert T, Mühlen H, Feinendegen LE, et al. Cerebral glucose metabolism in type 1 diabetic patients. Diabet Med 1994; 11: 205-209.
37. Selvarajah D, Wilkinson ID, Emery CJ, Shaw PJ, Griffiths PD, Gandhi R, et al. Thalamic neuronal dysfunction and chronic sensorimotor distal symmetrical polyneuropathy in patients with type 1 diabetes mellitus. Diabetologia 2008; 51: 2088-2092.
38. Tomlinson DR, Gardiner NJ. Glucose neurotoxicity. Nat Rev Neurosci 2008; 9: 36-45.
39. Figueroa-Romero C, Sadidi M, Feldman EL. Mechanisms of disease: the oxidative stress theory of diabetic neuropathy. Rev Endocr Metab Disord 2008; 9: 301-314.
40. Cameron NE, Cotter MA. Pro-inflammatory mechanisms in diabetic neuropathy: focus on the nuclear factor kappa B pathway. Curr Drug Targets 2008; 9: 60-67.
41. Consensus Development Conference on Standardized Measures in Diabetic Neuropathy. Proceedings of a consensus development conference on standardized measures in diabetic neuropathy. Diabetes Care 1992; 15 (Suppl 3): 1080-1107.
42. Paisley AN, Abbott CA, van Schie CH, Boulton AJ. A comparison of the Neuropen against standard quantitative sensory-threshold measures for assessing peripheral nerve function. Diabet Med 2002; 19: 400-405.
43. Ziegler D, Siekierka-Kleiser E, Meyer B, Schweers M. Validation of a novel screening device (NeuroQuick) for quantitative assessment of small nerve fiber dysfunction as an early feature of diabetic polyneuropathy. Diabetes Care 2005; 28: 1169-1174.
44. Viswanathan V, Snehalatha C, Seena R, Ramachandran A. Early recognition of diabetic neuropathy: evaluation of a simple outpatient procedure using thermal perception. Postgrad Med J 2002; 78: 541-542.
45. Martina IS, van Koningsveld R, Schmitz PI, van der MechéFG, van Doorn PA. Measuring vibration threshold with a graduated tuning fork in normal aging and in patients with polyneuropathy. J Neurol Neurosurg Psychiatry 1998; 65: 743-747.
46. Papanas N, Papatheodorou K, Christakidis D, Papazoglou D, Giassakis G, Piperidou H, et al. Evaluation of a new indicator test for sudomotor function (Neuropad) in the diagnosis of peripheral neuropathy in type 2 diabetic patients. Exp Clin Endocrinol Diabetes 2005; 113: 195-198.
47. Feldman EL, Stevens MJ, Thomas PK, Brown MB, Canal N, Greene DA. A practical two-step quantitative clinical and electrophysiological assessment for the diagnosis and staging of diabetic neuropathy. Diabetes Care 1994; 17: 1281-1289.
48. Young MJ, Boulton AJM, Macleod AF, Williams DRR, Sonksen PH. A multicentre study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population. Diabetologia 1993; 36: 150-154.
49. Bennett MI, Attal N, Backonja MM, Baron R, Bouhassira D, Freynhagen R, et al. Using screening tools to identify neuropathic pain. Pain 2007; 127: 199-203.
50. Quantitative sensory testing: a consensus report from the Peripheral Neuropathy Association. Neurology 1993; 43: 1050-1052.
51. Lauria G, Cornblath DR, Johansson O, McArthur JC, Mellgren SI, Nolano M, et al.; European Federation of Neurological Societies. EFNS guidelines on the use of skin biopsy in the diagnosis of peripheral neuropathy. Eur J Neurol 2005; 12: 747-758.
52. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-986.
53. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
54. Martin CL, Albers J, Herman WH, Cleary P, Waberski B, Greene DA, et al.; DCCT/EDIC Research Group. Neuropathy among the diabetes control and complications trial cohort 8 years after trial completion. Diabetes Care 2006; 29: 340-344.
55. ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560-2572.
56. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, et al.; VADT Investigators. Glucose control and vascular com-plications in veterans with type 2 diabetes. N Engl J Med 2009; 360: 129-139.
57. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008; 358: 580-591.
58. Boulton AJ, Vinik AI, Arezzo JC, Bril V, Feldman R, Freeman R, et al. Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes Care 2005; 28: 956-962.
59. Ang CD, Alviar MJ, Dans AL, Bautista-Velez GG, Villaruz-Sulit MV, Tan JJ, et al. Vitamin B for treating peripheral neuropathy. Cochrane Database Syst Rev 2008; 3: CD004573.
60. Stracke H, Gaus W, Achenbach U, Federlin K, Bretzel RG. Benfotiamine in diabetic polyneuropathy (BENDIP): results of a randomised, double blind, placebo-controlled clinical study. Exp Clin Endocrinol Diabetes 2008; 116: 600-605.
61. Ziegler D, Nowak H, Kempler P, Vargha P, Low PA. Treatment of symptomatic diabetic polyneuropathy with the antioxidant a-lipoic acid: a meta-analysis. Diabetic Med 2004; 21: 114-121.
62. Ziegler D, Ametov A, Barinov A, Dyck PJ, Gurieve I, Low PA, et al. Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial. Diabetes Care 2006; 29: 2365-2370.
63. Ziegler D, Low PA, Boulton AJM, et al. Antioxidant treatment with a-lipoic acid in diabetic polyneuropathy: a 4-year randomised double-blind trial (NATHAN 1 Study). Diabetologia 2007; 50 (Suppl 1): 63.
64. Ziegler D. Thioctic acid for patients with symptomatic diabetic neuropathy: a critical review. Treat Endocrinol 2004; 3: 1-17.
65. Finnerup NB, Otto M, McQuay HJ, Jensen TS, Sindrup SH. Algorithm for neuropathic pain treatment: an evidence based proposal. Pain 2005; 118: 289-305.
66. Dworkin RH, O'Connor AB, Backonja M, Farrar JT, Finnerup NB, Jensen TS, et al. Pharmacologic management of neuropathic pain: evidence-based recommendations. Pain 2007; 132: 237-251.
67. Ziegler D. Painful diabetic neuropathy. Advantage of novel drugs over old drugs? Diabetes Care 2009; 32 (Suppl 2): S414-S419.
68. Ziegler D. Painful diabetic neuropathy: treatment and future aspects. Diabetes Metab Res Rev 2008; 24 (Suppl 1): S52-S57.
69. Edelsberg J, Oster G. Summary measures of number needed to treat: how much clinical guidance do they provide in neuropathic pain? Eur J Pain 2009; 13: 11-16.
70. Wong MC, Chung JW, Wong TK. Effects of treatments for symptoms of painful diabetic neuropathy: systematic review. Br Med J 2007; 335: 87.
71. Otto M, Bach FW, Jensen TS, Br øsen K, Sindrup SH. Escitalopram in painful polyneuropathy: a randomized, placebo-controlled, cross-over trial. Pain 2008; 139: 275-283.
72. Kajdasz DK, Iyengar S, Desaiah D, Backonja MM, Farrar JT, Fishbain DA, e t al. D uloxetine for the management of diabetic peripheral neuropathic pain: evidence-based findings from post hoc analysis of three multicenter, randomized, double-blind, placebo-controlled, parallel-group studies. Clin Ther 2007; 29: 2536-2546.
73. Ziegler D, Pritchett YL, Wang F, Desaiah D, Robinson MJ, Hall JA, et al. Impact of disease characteristics on the efficacy of duloxetine in diabetic peripheral neuropathic pain. Diabetes Care 2007; 30: 664-669.
74. Hardy T, Sachson R, Shen S, Armbruster M, Boulton AJ. Does treatment with duloxetine for neuropathic pain impact glycemic control? Diabetes Care 2007; 30: 21-26.
75. Rowbotham MC, Goli V, Kunz NR, Lei D. Venlafaxine extended release in the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled study. Pain 2004; 110: 697-706.
76. Backonja M, Beydoun A, Edwards KR, Schwartz SL, Fonseca V, Hes M, et al. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus. JAMA 1998; 280: 1831-1836.
77. Freeman R, Durso-Decruz E, Emir B. Efficacy, safety, and tolerability of pregabalin treatment for painful diabetic peripheral neuropathy: findings from seven randomized, controlled trials across a range of doses. Diabetes Care 2008; 31: 1448-1454.
78. Grosskopf J, Mazzola J, Wan Y, Hopwood M. A randomized, placebo -controlled study of oxcarbazepine in painful diabetic neuropathy. Acta Neurol Scand 2006; 114: 177-180.
79. Beydoun A, Shaibani A, Hopwood M, Wan Y. Oxcarbazepine in painful diabetic neuropathy: results of a dose-ranging study. Acta Neurol Scand 2006; 113: 395-404.
80. Thienel U, Neto W, Schwabe SK, Vijapurkar U; Topiramate Diabetic Neuropathic Pain Study Group. Topiramate in painful diabetic polyneuropathy: findings from three double-blind placebo-controlled trials. Acta Neurol Scand 2004; 110: 221-231.
81. Vinik AI, Tuchman M, Safirstein B, Corder C, Kirby L, Wilks K, et al. Lamotrigine for treatment of pain associated with diabetic neuropathy: results of two randomized, double-blind, placebocontrolled studies. Pain 2007; 128: 169-179.
82. Mo J, Chen LL. Systemic lidocaine for neuropathic pain relief. Pain 2000; 87: 7-17.
83. Davies PS, Galer BS. Review of lidocaine patch 5% studies in the treatment of postherpetic neuralgia. Drugs 2004; 64: 937-947.
84. Ziegler D, Hidvégi T, Gurieva I, Bongardt S, Freynhagen R, Sen D, Sommerville K. Efficacy and safety of lacosamide in painful diabetic neuropathy. Diabetes Care 2010; Jan 12 [Epub ahead of print].
85. Mason L, Moore RA, Derry S, Edwards JE, McQuay HJ. Systematic review of topical capsaicin for the treatment of chronic pain. Br Med J 2004; 328: 991-995.
86. Harati Y, Gooch C, Swenson M, Edelman S, Greene D, Raskin P, et al. Double-blind randomized trial of tramadol for the treatment of the pain of diabetic neuropathy. Neurology 1998; 50: 1842-1846.
87. Watson CP, Moulin D, Watt-Watson J, Gordon A, Eisenhoffer J. Controlled-release oxycodone relieves neuropathic pain: a randomized controlled trial in painful diabetic neuropathy. Pain 2003; 105: 71-78.
88. Gimbel JS, Richards P, Portenoy RK. Controlled-release oxycodone for pain in diabetic neuropathy: a randomized controlled trial. Neurology 2003; 60: 927-934.
89. Gilron I, Bailey JM, Tu D, Holden RR, Weaver DF, Houlden RL. Morphine, gabapentin, or their combination for neuropathic pain. N Engl J Med 2005; 31: 1324-1334.
90. Hanna M, O'Brien C, Wilson MC. Prolonged-release oxycodone enhances the effects of existing gabapentin therapy in painful diabetic neuropathy patients. Eur J Pain 2008; 12: 804-813.
91. Pittler MH, Ernst E. Complementary therapies for neuropathic and neuralgic pain: systematic review. Clin J Pain 2008; 24: 731-733.
92. Tesfaye S. Painful diabetic neuropathy: aetiology and nonpharmacological treatment. In: Veves A, ed. Clinical Management of Diabetic Neuropathy. Totowa, NJ: Humana Press, 1998; 369-386.
93. Abuaisha BB, Costanzi, Boulton AJM. Acupuncture for the treatment of chronic painful peripheral diabetic neuropathy: a long-term study. Diabetes Res Clin Pract 1998; 39: 115-121.
94. Kumar D, Alvaro MS, Julka IS, Marshall HJ. Diabetic peripheral neuropathy. Effectiveness of electrotherapy and amitriptyline for symptomatic relief. Diabetes Care 1998; 21: 1322-1325.
95. Reichstein L, Labrenz S, Ziegler D, Martin S. Effective treatment of symptomatic diabetic polyneuropathy by high-frequency external muscle stimulation. Diabetologia 2005; 48: 824-828.
96. Bosi E, Conti M, Vermigli C, Cazzetta G, peretti E, Cordoni MC, et al. Effectiveness of frequency-modulated electromagnetic neural stimulation in the treatment of painful diabetic neuropathy. Diabetologia 2005; 48: 817-823.
97. Tesfaye S, Watt J, Benbow SJ, Pang KA, Miles J, MacFarlane IA. Electrical spinal-cord stimulation for painful diabetic peripheral neuropathy. Lancet 1996; 348: 1696-1701.
98. Clifft JK, Kasser RJ, Newton TS, Bush AJ. The effect of monochromatic infrared energy on sensation in patients with diabetic peripheral neuropathy: a double-blind, placebo-controlled study. Diabetes Care, 2005; 28: 2896-2900.
99. Lavery LA, Murdoch DP, Williams J, Lavery DC. Does anodyne light therapy improve peripheral neuropathy in diabetes? A double-blind, sham-controlled, randomized trial to evaluate monochromatic infrared photoenergy. Diabetes Care 2008; 31: 316-321.
100. Chaudhry V, Stevens JC, Kincaid J, So YT; Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Practice Advisory: utility of surgical decompression for treatment of diabetic neuropathy: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2006; 66: 1805-1808.
101. Chaudhry V, Russell J, Belzberg A. Decompressive surgery of lower limbs for symmetrical diabetic peripheral neuropathy. Cochrane Database Syst Rev 2008; 16 (3): CD006152.